Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Haemolysis due to formaldehyde-induced anti-N-like antibodies in haemodialysis patients (1979)
    Springer
    Journal of molecular medicine 57 (1979), S. 673-679 
    Details
    ISSN: 1432-1440
    Keywords: Formaldehyd ; Anti-N-artige Antikörper ; Immunhämolyse ; Hämodialyse ; renale Anämie ; Formaldehyde ; Anti-N-like antibodies ; Immunohaemolysis ; Haemodialysis ; Renal anaemia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary During reuse of formaldehyde sterilized Kiil-dialysers, red cell survival, measured by means of51Cr t/2, was significantly reduced (p〈0.001) in 16 patients with anti-N-like positive sera, when compared with 19 antibody negative control patients (Mean±SD: 16.5±2.7 versus 22.4±3.1 days.) In antibody negative patients (n=10) replacement of form-aldehyde sterilized dialysers by ethylene-oxide sterilized disposable dialysers resulted in a significant increase (p〈0.002) of51Cr t/2 (Mean±SD, days: Kiil-dialyser 16.3±1.9; disposable dialyser 20.3±3.5). This improvement took place, although antibody titres persisted during the51Cr-measurements and declined thereafter only slowly. In antibody negative patients (n=6) red cell survival did not increase, when formaldehyde as a sterilant was avoided. In antibody positive patients mean haematocrit rose significantly (p〈0.05), whereas in none of the antibody negative patients a definite change of haematocrit occurred. The data demonstrate, that formaldehyde sterilisation of dialysers may cause antibody-mediated haemolysis contributing to the extent of renal anaemia. This immunohaemolysis may be corrected, in spite of continuing antibody persistance, when formaldehyde exposure is totally avoided, or possibly when minimized.
    Notes: Zusammenfassung Während der Wiederverwendung Formaldehyd-sterilisierter Kiil-Dialysatoren war die mit51Cr bestimmte Erythrocytenüberlebenszeit bei 16 Patienten mit Anti-N-artigen Antikörpern significant (p〈0,001) kürzer als bei 19 Antikörper-negativen Kontrollpatienten (MW±SD: 16,5±2,7 bzw. 22,4±3,1 Tage). Bei Antikörper-positiven Patienten (n=10) führte das Umsetzen von Formaldehyd-sterilisierten Kiil-Dialysatoren auf Ethylenoxid-sterilisierte Einmaldialysatoren vergleichbarer Effektivität zu einem sofortigen, signifikanten (p〈0,002) Anstieg der Erythrocytenüberlebenszeit (MW±SD: 16,3±1,9 Tage, Kiil-Dialysator; 20,3±3,5 Tage Einmaldialysator). Die Antikörper-Titer blieben während der Messung der Erythrocytenüberlebenszeit unverändert, danach fielen sie im Verlauf von Monaten langsam ab. Bei Antikörper-negativen Kontrollpatienten (n=6) führte das Umsetzen von Formaldehyd-sterilisierten Kiil-Dialysatoren auf die Ethylenoxid-sterilisierten Einmaldialysatoren nicht zum Anstieg der Erythrocytenüberlebenszeit. Bei den Antikörper-positiven Patienten stieg der mittlere Hämatokritwert nach dem Umsetzen signifikant (p〈0,05) an, dagegen kam es nach dem Umsetzen bei keinem der Antikörper-negativen Patienten zu einer gerichteten Veränderung der Hämatokritwerte. Die Untersuchungen belegen, daß die Formaldehyd-Sterilisation von Dialysatoren zu einer Antikörper-vermittelten Hämolyse führen kann, die zum Ausmaß der renalen Anämie dieser Patienten beiträgt. Diese Immunhämolyse kann, auch bei Persistenz der Anti-N-artigen Antikörper, zumindest teilweise verhindert werden, wenn eine weitere Formaldehyd-Exposition des Patienten vermieden wird.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01477668
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Medikamentöse Behandlung der chronisch verlaufenden Glomerulonephritiden: Pro (1985)
    Springer
    Journal of molecular medicine 63 (1985), S. 967-977 
    Details
    ISSN: 1432-1440
    Keywords: Drug treatment ; Chronic glomerulonephritis ; Prospective controlled therapeutic trials ; Medikamentöse Behandlung ; Chronische Glomerulonephritis ; Prospektive kontrollierte Therapiestudien
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Pathogenese und Mechanismen der Progression chronischer Glomerulonephritiden (GN) sind bisher nicht geklärt. Dennoch gibt es erfolgversprechende, prospektive, kontrollierte Therapie-Studien sowie neue Therapie-Ansätze. So wurden beispielsweise Patienten mit idiopathischermembranöser GN monatlich mit Chlorambucil (0,2 mg/kg/Tag) oder Prednison (0,6 mg/kg/Tag) im Wechsel über sechs Monate behandelt. Im Vergleich zu den unbehandelten zeigte sich bei den behandelten Patienten innerhalb von drei Jahren ein günstiger Verlauf der Nierenfunktionsparameter. In einer anderen Studie erhielten Patienten mitmembrano-proliferativer GN Typ I über ein Jahr täglich 975 mg Aspirin und 225 mg Dipyridamol. Bei den behandelten trat im Gegensatz zu den nichtbehandelten Patienten eine Stabilisierung der Nierenfunktion und eine Normalisierung der vorher beschleunigten Thrombozyten-Überlebensrate ein. In einer weiteren kontrollierten Therapie-Studie wurde gezeigt, daß die Langzeit-Prognose derdiffus-proliferativen Lupus-Nephritis (Typ IV WHO) besser ist, wenn eine kombinierte Behandlung mit Cyclophosphamid (100 mg/Tag) und Prednison (30 mg/Tag) über mehrere Monate erfolgt als eine alleinige Prednison-Behandlung (40 mg/Tag). Dagegen gibt es bisher bei einigen Formen der chronischen GN, z.B. derIgA-Nephritis, noch keine Evidenz für eine Therapie, die den Verlauf der Nephritis entscheidend beeinflussen kann. Neuere Therapie-Ansätze, wie die Gabe von Cyclophosphamid (über drei Monate) oder von Cyclosporin A beiglomerulärer Minimal-Läsion mit steroid-abhängigem nephrotischen Syndrom, werden in Therapie-Studien überprüft. Einige kontrolliert durchgeführte Untersuchungen weisen darauf hin, daß die Progression der chronischen GN durch eine Diät mit geringem Proteingehalt günstig beeinflußt werden kann. Der Einfluß von Eicosanoiden und deren Inhibitoren auf den Verlauf chronischer GN, speziell der glomerulären Sklerosierung, ist bisher noch nicht ausreichend untersucht worden. Insgesamt ist eine Entwicklung zu einer zunehmend differenzierten medikamentösen Behandlung der chronischen GN festzustellen, die generell durch die Bereitschaft zu einem aktiven therapeutischen Vorgehen unterstützt werden sollte.
    Notes: Summary This paper sets out the arguments for drug treatment of chronic glomerulonephritides (GN). Although the pathogenesis and mechanism of progression of chronic GN remained to be clarified, on the basis of controlled studies performed to date, there is a strong case to be made for an aggressive treatment approach to this disease spectrum. For instance, in patients with idiopathicmembranous glomerulonephritis a six months treatment with chlorambucil (0.2 mg/KG/day) or prednisone (0.6 mg/KG/day) each given once a day over a period of three months has recently been shown to improve the outcome of the renal functional parameters after three years follow up. In another controlled trial a daily dose of 225 mg dipyridamole and 975 mg aspirin given over 12 months in patients withmembrano-proliferative GN type I has been reported to normalize the increased platelet consumption rate and to stabilize the glomerular filtration rate. A third trial has demonstrated that the combined use of cyclophosphamide (100 mg/day) and prednisone (30 mg/day) over several months was superior to the use of prednisone alone (40 mg/day) in improving the long-term prognosis ofdiffuse-proliferative lupus nephritis (type IV, WHO). In some entities, however, as in IgA-nephritis there is still no evidence for a specific treatment improving the course of the chronic glomerular disease. Other therapeutic problems have to be solved: thus, in patients withminimal change nephropathy with a steroid dependent nephrotic syndrome the benefit of cyclophosphamide (given over three months) or of cyclosporin A is still being investigated. Furthermore, there is some evidence that progression of chronic GN, particularly that of glomerular sclerosing, can be prevented by a low protein diet. The role of eicosanoides and their inhibitors in this context has not yet been fully investigated. The different drug trials and new therapeutic concepts indicate a rapid development of chronic GN treatment. Therefore, a failure to treat actively is difficult to understand.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01738152
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Die Rolle des Erythropoietinmangels in der Pathogenese der renalen Anämie (1979)
    Springer
    Journal of molecular medicine 57 (1979), S. 1031-1036 
    Details
    ISSN: 1432-1440
    Keywords: Renal anemia ; Pathogenesis ; Erythropoietin deficiency ; Renale Anämie ; Pathogenese ; Erythropoietinmangel
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Es wird eine Übersicht gegeben über klinische Untersuchungen, die mit einem hochsensiblen in-vitro Erythropoietin Assay (foetale Mäuseleberzellkultur) zur Klärung der umstrittenen Rolle des Erythropoietinmangels in der Pathogenese der renalen Anämie an großen Patientenpopulationen durchgeführt wurden. Die Studien betrafen: a.) chronisch Nierenkranke mit variierender Funktionsein-schränkung in der Vordialysephase b.) nicht nephrektomierte und anephrische chronische Dialysepatienten. Die bisher vorliegenden Ergebnisse belegen, daß die Anfangsphase der renalen Anämie mit einem kompensatorischen Anstieg der Serumerythropoietinkonzentration einhergeht und somit ein Erythropoietinmangel nicht die primäre Ursache dieser Anämie sein kann; lediglich ein relativer Erythropoietinmangel ist anzunehmen. Erst in der Terminalphase der Niereninsuffizienz wird der Erythropoietinmangel absolut, so bei 50% der untersuchten chronischen, nichtnephrektomierten Hämodialysepatienten und bei allen anephrischen Patienten. An einzelnen Patienten läßt sich aber selbst in der terminalen Niereninsuffizienz eine Regulierbarkeit der Serumerythropoietinkonzentration über den Hämatokrit im Sinne eines negativen feedback nachweisen, der auf einem subnormalen Hämatokritniveau arbeitet.
    Notes: Summary A review is given of clinical studies performed by use of a highly sensitive in-vitro erythropoietin assay (fetal mouse livercell culture) in large patients' populations to clarify the controversial role of erythropoietin deficiency in the pathogenesis of renal anemia. Studies involved a.) patients with chronic renal disease and varying degree of renal insufficiency in the predialysis phase b.) non-nephrectomized and anephric patients on regular hemodialysis treatment. The data available demonstrate that the initial phase of renal anemia is accompanied by a compensatory increase of serumerythropoietin concentration and therefore erythropoietin deficiency has to be excluded as a primary cause of the anemia of renal failure; merely a relative lack of erythropoietin seems to exist. In the terminal phase of renal failure, erythropoietin deficiency becomes absolute, such in 50% of the investigated non-nephrectomized hemodialysis patients and in all anephric patients. However in individual patients even in terminal renal failure a sustained regulatory feedback mechanism between serume-rythropoietin concentration and hematocrit, probably working at lower hematocrit level, could be demonstrated.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01479988
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Autonome Kreislaufregulation in der Urämie (1980)
    Springer
    Journal of molecular medicine 58 (1980), S. 1037-1042 
    Details
    ISSN: 1432-1440
    Keywords: Uremic autonomic neuropathy ; Baroreflex ; Efferent sympathetic limb ; Circulatory regulation ; Urämische autonome Neuropathie ; Baroreflex ; Sympathicus ; Kreislaufregulation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Die urämische autonome Neuropathie führt zu Störungen der Funktion des Baroreflexes. Aus der Literatur geht hervor, daß die wesentlichen Defekte den afferenten Reflexbogen sowie den efferenten cardialen Vagus betreffen, während die sympathische Funktion des efferenten Schenkels intakt bleibt. Eigene Befunde, an chronischen Hämodialysepatienten während Orthostase und Volumenentzug erhoben, belegen ebenfalls eine qualitativ und quantitativ adäquate Antwort des efferenten Sympathicus sowie eine erhaltene Ansprechbarkeit der Rezeptoren des Endorgans. Die autonome Neuropathie disponiert zur symptomatischen Hypotension bei Volumenentzug während der Dialysebehandlung. Zusätzlich führt die Hämodialysebehandlung selbst zu einer noch ungeklärten Hemmung der sympathischen Reaktion auf Volumenentzug. Die autonome Neuropathie disponiert bei Volumenbelastung zur arteriellen Hypertonie.
    Notes: Summary Uremic autonomic neuropathy leads to impaired function of the baroreflex. The main defect, according to literature, is located in the afferent limb of the reflex arc and in the efferent cardiac vagus nerve, whereas the sympathetic part of the efferent arc is still intact. Own results, obtained in hemodialysis patients during orthostasis and volume removal induced sympathetic stimulation, showed a qualitatively and quantitatively adequate sympathetic response and also an adequate end organ receptor response. Autonomic nervous neuropathy predisposes to volume removal related symptomatic hypotension during hemodialysis treatment. In addition hemodialysis treatment per se induces a so far unexplained interference with sympathetic response to volume removal. The autonomic neuropathy also predisposes to development of hypertension in response to volume load.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01476874
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis (1994)
    Springer
    Journal of molecular medicine 72 (1994), S. 277-282 
    Details
    ISSN: 1432-1440
    Keywords: Idiopathic membranous glomerulonephritis ; Treatment
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Because of the high rate of spontaneous remission, treatment of membranous nephropathy with prednisolone and chlorambucil is still controversial. The aim of this study was to give this therapy only to those patients at risk of developing renal insufficiency and to test the efficacy of a low-dose therapeutic regimen. Seventeen patients with more than 10 g protein excretion per day (mean 16.9) and/or a deterioration in renal function (mean serum creatinine, 162 μmol/l) were included. Serum total protein, serum lipids, proteinuria, serum creatinine, and blood pressure were measured, along with the diuretic and antihypertensive medication. The observation time before the start of treatment was 27 ± 27 months. Steroids were given during months 1, 3, and 5 (methylprednisolone 3 × 500 mg intravenously) prednisolone 0.5 mg/kgBW daily per os for 1 week, then tapered by 0.1 mg/kg BW/week for 1 month. Chlorambucil was given during months 2, 4, and 6 at a dose of 0.12 mg/kgBW daily. At the end of treatment proteinuria had significantly decreased (mean of all patients, 7.8 ± 1.4 g/d) in all patients. Six months after the end of treatment proteinuria was significantly lower than at baseline in 14 of 17 patients. Hypoproteinemia and hyperlipidemia had improved; diuretic and antihypertensive medication were reduced. Elevated serum creatinine decreased in 7 of 9 patients (pretreatment, 227 ± 39 μmol/1; 6 months, 176 ± 28 μmol/l). Nonresponders with respect to serum creatinine responded with respect to proteinuria. Regarding adverse effects, two patients complained of dyspepsia while taking steroids; during chlorambucil treatment two patients experienced nausea and lack of appetite, and one developed leukopenia (1600/μl). Chlorambucil was stopped and cell counts normalized 2 weeks later. We conclude that low-dose prednisolone/chlorambucil is both safe and efficient in the majority of patients with severe membranous nephropathy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00180040
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency (1989)
    Springer
    European journal of clinical pharmacology 37 (1989), S. 249-256 
    Details
    ISSN: 1432-1041
    Keywords: ramipril ; renal insufficiency ; hypertension ; pharmacokinetics ; ramiprilat
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary In an open trial, the pharmacokinetics of ramipril and its active metabolite ramiprilat were studied in 25 hypertensive patients with various degrees of renal insufficiency given 5 mg ramipril p.o. for 14 days. Ramipril was rapidly absorbed and reached a peak concentration after 1–2 h. Cmax was greater in patients with severe renal insufficiency, which might indicate a reduced renal elimination rate, although, the rapid decline of the concentration-time curve for ramipril was almost independent of renal function. The mean initial apparent half-lives on Days 1 and 12, respectively, were 2.8 and 3.4 h (Group I: creatinine clearance 5–15 ml/min), 1.8 and 2.3 h (Group II: creatinine clearance 15–40 ml/min), and 1.9 and 1.9 h (Group III: creatinine clearance 40–80 ml/min). No accumulation was observed after multiple dosing. In contrast, the kinetics of its active acid metabolite ramiprilat was significantly influenced by renal function. The mean times to the peak plasma concentration were 5.7 h in Group I, 4.4 h in Group II and 3.8 h in Group III. The initial decline in plasma ramiprilat was dependent upon renal function; the mean initial apparent half-lives (Days 1 and 12, respectively) were 16.0 and 14.8 h (Group I), 10.1 and 9.5 h (Group II) and 10.6 and 8.0 h (Group III). Mean trough concentrations and absolute accumulation also increased with worsening renal function, and the renal clearance of ramiprilat was significantly correlated with the creatinine clearance. The subsequent long terminal phase at low plasma ramiprilat concentrations represented slow dissociation of the ACE-inhibitor complex. The study indicates that in patients with severe renal insufficiency (creatinine clearance below 30 ml/min) smaller doses of ramipril are required than in patients with normal or borderline renal function.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00679779
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Cyclosporin A inhibits PGE"2 release from vascular smooth muscle cells
    Amsterdam : Elsevier
    Biochemical and Biophysical Research Communications 147 (1987), S. 542-549 
    Details
    ISSN: 0006-291X
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology , Physics
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1016/0006-291X(87)90965-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    The safety of ranitidine in over a decade of use (1997)
    Oxford BSL : Blackwell Science
    Alimentary pharmacology & therapeutics 11 (1997), S. 0 
    Details
    ISSN: 1365-2036
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Background: Ranitidine hydrochloride (Zantac) is one of the most extensively studied and widely used drugs of all time. This has provided an excellent opportunity to define its safety profile. Methods: Data from 189 controlled clinical trials in which more than 26000 patients received daily doses of ranitidine for 4 weeks or more were reviewed. More than 80% of patients were treated with up to 300 mg ranitidine daily; the remaining patients received doses of up to 1200 mg daily. Eighty-seven trials were placebo controlled. Analyses of post-marketing surveillance and a database of all spontaneously reported adverse events were also evaluated. Results: Overall in the clinical trial programme adverse events were reported by 20% of those receiving ranitidine compared with 27% of those receiving placebo. The pattern of events was similar in all treatment groups with no evidence of dose-related toxicity in regimens encompassing an eightfold range of therapeutic doses. Similarly in a programme of studies designed to evaluate a dose of ranitidine of 75  mg for non-prescription (over-the-counter) use in the treatment of heartburn, ranitidine was not associated with an adverse event profile distinct from that of placebo. Analysis of spontaneously reported adverse event data allowed identification of rare idiosyncratic events. Conclusions: Review of data from a large population of controlled clinical trials with analyses of postmarketing surveillance studies and spontaneously reported adverse events confirmed the excellent safety profile of ranitidine.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1365-2036.1997.136312000.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors (2004)
    Oxford, UK : Blackwell Science Ltd
    Alimentary pharmacology & therapeutics 20 (2004), S. 0 
    Details
    ISSN: 1365-2036
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Aim : To assess the pharmacokinetics of alosetron, its effect on in vivo enzyme activities, and influence of demographic factors during repeated dosing.Methods : Thirty healthy men and women received 1 mg oral alosetron twice-daily for 29.5 days and a single oral dose of a metabolic probe cocktail before and on the last day of alosetron dosing. Serum alosetron concentrations were measured on days 1, 8, 15, 22 and 29. Probe-substrate and metabolite concentrations were measured after each cocktail dose.Results : Alosetron accumulation in serum was negligible. Exposure to alosetron did not alter probe-metabolite/substrate ratios associated with CYP2C19, 2E1, 2C9, or 3A4 activity, but modestly decreased those associated with CYP1A2 and N-acetyltransferase activity. Systemic exposure to alosetron was higher in women, positively correlated with age and body mass index, and negatively correlated with CYP1A2 activity. Incidence of constipation was higher in women, but not associated with alosetron concentration.Conclusions : Single dose data can reliably predict the pharmacokinetics of alosetron after repeated doses. Alosetron exhibits limited potential for inhibition of cytochrome P450-mediated metabolism. Interindividual differences in alosetron pharmacokinetics associated with demographic factors may be related to strong dependence on metabolism by CYP1A2.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1365-2036.2004.02031.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 10
    Electronic Resource
    Electronic Resource
    Transplantathyperparathyreoidismus —Tumorähnliches Wachstum und autonome Funktion menschlicher Autotransplantate von hyperplastischen Epithelkörperchen (1982)
    Springer
    Langenbeck's archives of surgery 356 (1982), S. 191-204 
    Details
    ISSN: 1435-2451
    Keywords: Secondary hyperparathyroidism ; Total parathyroidectomy ; Autotransplantation ; Transplantation tumor
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bei 41 Patienten mit chronisch globaler Niereninsuffizienz und sekundärem Hyperparathyreoidismus wurde eine totale Parathyreoidektomie und Autotransplantation von Epithelkörperchengewebe in die fistelfreie Unterarmmuskulatur durchgeführt. Innerhalb von 7–33 Monaten entwickelten 5 Patienten ein Transplantatrezidiv im Unterarm. Die morphologischen und klinischen Aspekte des Transplantathyperparathyreoidismus rücken die Regenerate im Unterarm in die Nachbarschaft eines malignen Wachstums. Bei Abwägung der Erfolge und der Risiken dieses Verfahrens nach 5jähriger Beobachtung kann die Autotransplantation beim sekundären Hyperparathyreoidismus nicht empfohlen werden. Ausschlaggebend ist die hierfür zwar morphologisch vorerst nicht nachgewiesene, aber durchaus vorstellbare Entwicklung eines Transplantatcarcinoms.
    Notes: Summary The results of clinical and morphologic studies performed in 41 patients with chronic, renal failure and secondary hyperparathyroidism, who had total parathyroidectomy and autotransplantation of parathyroid tissue into the forearm muscle are presented. In five cases, 7–33 months after autotransplantation we found transplantation tumors developing in the forearm. Explanted grafts showed invasive growth of parathyroid tissue in the adjacent structures, into the musculature and blood vessels. The increased incidence of mitosis otherwise seen as evidence of malignant neoplasia of parathyroid tumors, indicated atypical focal proliferation of the transplanted tissue. This is justification for not performing transplantations any more in the treatment of renal osteodystrophy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01261757
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...